Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.7
4.6
Journals
Molecules
Special Issues
Recent Advances in Nanomedicine and Nanovaccine Development
molecules-logo
Submit to Molecules Review for Molecules Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Recent Advances in Nanomedicine and Nanovaccine Development

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Applied Chemistry".

Deadline for manuscript submissions: closed (15 September 2021) | Viewed by 5521

Special Issue Editors

Dr. Sabiruddin Mirza

E-Mail Website
Guest Editor
School of Engineering and Applied Sciences Cambridge, Harvard University, Cambridge, MA, USA
Interests: nanomedicines; drug delivery systems; biologics; combination drugs; multifunctional nanocarriers; biomaterials surface modification; nanocrystals; solid form screening; cocrystals; material analysis; preformulation; preclinical drug development screens; microfluidics; anticancer drug delivery systems
Special Issues, Collections and Topics in MDPI journals
Dr. Inna Miroshnyk

E-Mail Website
Guest Editor
Lake Erie College of Osteopathic Medicine (LECOM), USA
Interests: drug delivery; nanotechnologies; microfluidics; continuous manufacturing

Special Issue Information

Dear Colleagues,

Nanomedicine is an emerging field that fosters the development of novel concepts in drug delivery and the exploration of innovative treatment strategies to combat major disease states. Synthetically manufactured nanoparticles, biomimetic or bio-inspired nanocarriers, nanocomposites, and nanostructured materials with optimized properties are being considered as a new paradigm in the therapy of many devastating illnesses, including infectious diseases.  

This Special Issue “Recent Advances in Nanomedicine and Nanovaccine Development” is dedicated to expert papers dealing with the novel nanotechnology-inspired delivery systems of small drug molecules or biotherapeutics. Topics may also include any aspects of smart nanomaterials that have the potential to be applied in clinical practice. We invite investigators to contribute original research article, as well as review articles that will stimulate the continuing efforts in this exciting and continuously expanding field.

Dr. Sabiruddin Mirza
Dr. Inna Miroshnyk
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • functional materials
  • nanotechnology
  • nanovaccines
  • drug delivery systems
  • targeted drug delivery

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

27 pages, 1476 KiB  
Review
Chitosan Nanoparticle-Based System: A New Insight into the Promising Controlled Release System for Lung Cancer Treatment
by Cha Yee Kuen and Mas Jaffri Masarudin
Molecules 2022, 27(2), 473; https://0-doi-org.brum.beds.ac.uk/10.3390/molecules27020473 - 12 Jan 2022
Cited by 35 | Viewed by 4469
Abstract
Lung cancer has been recognized as one of the most often diagnosed and perhaps most lethal cancer diseases worldwide. Conventional chemotherapy for lung cancer-related diseases has bumped into various limitations and challenges, including non-targeted drug delivery, short drug retention period, low therapeutic efficacy, [...] Read more.
Lung cancer has been recognized as one of the most often diagnosed and perhaps most lethal cancer diseases worldwide. Conventional chemotherapy for lung cancer-related diseases has bumped into various limitations and challenges, including non-targeted drug delivery, short drug retention period, low therapeutic efficacy, and multidrug resistance (MDR). Chitosan (CS), a natural polymer derived from deacetylation of chitin, and comprised of arbitrarily distributed β-(1-4)-linked d-glucosamine (deacetylated unit) and N-acetyl-d-glucosamine (acetylated unit) that exhibits magnificent characteristics, including being mucoadhesive, biodegradable, and biocompatible, has emerged as an essential element for the development of a nano-particulate delivery vehicle. Additionally, the flexibility of CS structure due to the free protonable amino groups in the CS backbone has made it easy for the modification and functionalization of CS to be developed into a nanoparticle system with high adaptability in lung cancer treatment. In this review, the current state of chitosan nanoparticle (CNP) systems, including the advantages, challenges, and opportunities, will be discussed, followed by drug release mechanisms and mathematical kinetic models. Subsequently, various modification routes of CNP for improved and enhanced therapeutic efficacy, as well as other restrictions of conventional drug administration for lung cancer treatment, are covered. Full article
(This article belongs to the Special Issue Recent Advances in Nanomedicine and Nanovaccine Development)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop